1309 GMT - AstraZeneca's revenue miss in oncology segment should concern investors but its long-term story seems intact, Barclays analysts say in a note. The British pharma giant posted mixed 1Q results as some of its oncology and rare disease drugs fell short of company-compiled sales consensus, the analysts say. "While we believe investors would question the oncology misses, important catalyst readouts planned for later this year and AstraZeneca being less susceptible to the ever-emerging tariff situation in the U.S., we see AstraZeneca as best positioned in our coverage," they say. Shares are down 0.3% at 104.90 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 29, 2025 09:09 ET (13:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。